Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Trial ID or NCT#

NCT00186277

Status

not recruiting iconNOT RECRUITING

Purpose

To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.

Official Title

Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology

View on ClinicalTrials.gov